摘要
如今,中东地区有超过三千二百万的糖尿病患者,预计到2040这个数字将翻一番。与欧洲和北美形成鲜明对比,尽管流行率很高在ME糖尿病方面,有关该地区糖尿病发病率和类型的流行病学数据非常有限。青少年的成熟型糖尿病(Mody)是一种代表单基因糖尿病的亚型。2-5%的糖尿病患者。本病为常染色体显性遗传模式,以35岁以下β细胞异常为特征。到目前为止,有15种不同的MODY表单已被确认;每一个都有不同的遗传病因。MODY在1型糖尿病和2型糖尿病之间被误诊是很常见的。因此,准确的基因诊断对于个体来说是至关重要的。e治疗及改善血糖控制。新技术,如下一代测序(NGS),为筛选和识别导致MODY突变提供了极好的选择。在这场革命中我们总结了每种MODY型的主要临床和遗传特征。此外,我们还阐明了在ME地区开展的MODY研究。
关键词: 青少年的成熟型糖尿病,中东地区的单基因糖尿病,常染色体显性模式,血糖,下一代测序。
Current Molecular Medicine
Title:Maturity-Onset Diabetes of the Young: An Overview with Focus on the Middle East
Volume: 17 Issue: 8
关键词: 青少年的成熟型糖尿病,中东地区的单基因糖尿病,常染色体显性模式,血糖,下一代测序。
摘要: Today, there are more than 32 million patients with diabetes in the Middle East (ME), the number is expected to double by 2040. In contrast to Europe and North America and despite the high prevalence of diabetes in ME, epidemiological data about incident and types of diabetes in the region is very limited.
Maturity-onset diabetes of the young (MODY) is a subtype of monogenic diabetes representing 2-5% of all diabetes patients. The disease is autosomal dominant mode of inheritance characterized by β-cell malfunction below the age of 35 years. To date, there are 15 different MODY forms that have been identified; each has a distinct genetic etiology.
It is very common that MODY is misdiagnosed between with type 1 or type 2 diabetes. Hence, accurate genetic diagnosis is crucial to individualize the treatment and to improve glycaemia control. New technologies such as next-generation sequencing (NGS) offer an excellent alternative to screen and identify causative MODY mutations. In this review, we summarize the main clinical and genetic characteristics for each MODY form. In addition, we shed light on MODY studies that have been executed in the ME region.
Export Options
About this article
Cite this article as:
Maturity-Onset Diabetes of the Young: An Overview with Focus on the Middle East, Current Molecular Medicine 2017; 17 (8) . https://dx.doi.org/10.2174/1566524018666180222121158
DOI https://dx.doi.org/10.2174/1566524018666180222121158 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research Risks Associated with SGLT2 Inhibitors: An Overview
Current Drug Safety Alcoholisms Evolutionary and Cultural Origins
Current Drug Abuse Reviews Adipokines, Metabolism and the Immune Response in the Regulation of Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology The Impact of a New Best Practice Advisory on the Management of Diabetic Ketoacidosis
Current Diabetes Reviews Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist
Mini-Reviews in Medicinal Chemistry Epidemiology of Type 1 Diabetes in Latin America
Current Diabetes Reviews Clinical and Forensic Signs Related to Opioids Abuse
Current Drug Abuse Reviews Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Efficacy and Cardiovascular Safety of SGLT2 Inhibitors
Current Drug Safety Roles of Calcium and Tyrosine Kinases in the Pathogenesis of Type 2 Diabetes Mellitus
Current Enzyme Inhibition Antifungal Agents in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods
Current Computer-Aided Drug Design Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use
Current Drug Safety Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature
Current Psychopharmacology Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature
Current Clinical Pharmacology Diabetes Mellitus and SARS-CoV-2 Infection: Pathophysiologic Mechanisms and Implications in Management
Current Diabetes Reviews